Video from ASH 2021: Gene therapy 2.0: The latest in gene editing

Dec 13, 2021
2021 12 10 19 28 1244 Ash 2021 Sign 400

The latest technologies in gene editing and gene therapy for treating genetic blood disorders were the focus of a dedicated session at the American Society of Hematology (ASH) 2021 meeting in Atlanta.

The presentations compared new approaches to gene editing with more established approaches in the field, according to Leah Cepko, a science advisor with Science and Medicine Group, parent company of LabPulse.com. Click on the video below to learn more.


Latest in Gene expression
Dna Sequence Shadow Social
Molecular diagnostic test study continues EET benefit assessment
April 2, 2024
Dna Cancer Cell Social
MIT team develops genome-editing approach for cancer mutation screening
March 22, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Dna Sequencing Genome Social
Polygenic risk score tests don’t meet expectations, U.K. study shows
October 26, 2023
Related Stories
2021 12 10 19 28 1244 Ash 2021 Sign 400
Hematology
Video from ASH 2021: Sickle-cell patients, activists tell their stories
2021 12 15 17 51 2318 Sekeres Mikkael
Leukemia
Video from ASH 2021: Advances in treating myeloid disorders
2021 12 10 19 28 1244 Ash 2021 Sign 400
Pathology, histology
90% is not good enough: How AI will reshape hemopathology
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Gene expression
Molecular diagnostic test study continues EET benefit assessment
By Liz Carey
A molecular oncology gene expression profiling (GEP) test for breast cancer biomarkers may influence extended endocrine therapy (EET) treatment decisions, according to an impact study.
April 2, 2024
Dna Sequence Shadow Social
MIT team develops genome-editing approach for cancer mutation screening
By Matt Limb
Scientists say they have developed a method to screen cancer-associated genetic mutations more easily and quickly than any existing approach.
March 22, 2024
Dna Cancer Cell Social
Weill Cornell study may support new prognostic test for prostate tumor spread
By LabPulse.com staff writers
Scientists working in the department of pathology and laboratory medicine at Weill Cornell Medicine have found that certain noncancerous cells may be useful for assessing prostate tumors and their potential to spread.
January 16, 2024
Cancer Cells Prostate Social
Polygenic risk score tests don’t meet expectations, U.K. study shows
By Matt Limb
Polygenic risk scores “perform poorly in screening and prediction of common disease,” failing to identify nearly 90% of patients who develop disease, according to a U.K. study.
October 26, 2023
Dna Sequencing Genome Social
Polygenic risk scores from multi-ancestry GWASs more accurate in diverse groups: Study
By LabPulse.com staff writers
Polygenic risk scores (PRS) derived from multi-ancestry genome-wide association studies (GWASs) outperform PRSs based on single-ancestry GWASs in underrepresented populations, new research shows.
September 21, 2023
Genome Sequence Barcode Social
Castle Biosciences Pittsburgh lab receives N.Y. state permit
By LabPulse.com staff writers
Castle Biosciences has received a clinical laboratory permit from the New York State Department of Health for its Pittsburgh laboratory.
September 13, 2023
Lab Scientist Biosafety Social
Gene expression test may improve diagnosis of febrile childhood diseases
By Matt Limb
A simple blood test based on patterns of gene expression could radically improve and speed up the diagnosis of febrile childhood diseases, say researchers.
August 30, 2023
Child Hospital Social
Gene-specific approach recommended for variant pathogenicity prediction
By Matt Limb
A research team investigated the efficacy of gene-specific supervised machine learning in predicting the pathogenicity of rare BRCA1/2 missense variants compared to the disease-specific approach.
August 22, 2023
Cell Gene Therapy Dna Social
CareDx lands Medicare coverage for heart transplant surveillance testing
By Nick Paul Taylor
The testing service, branded HeartCare, features AlloMap Heart and AlloSure Heart, both of which have individual Medicare coverage.
August 9, 2023
Cardiac Heart Eeg Social
CareDx reports 13% second-quarter revenue decrease from previous year
By LabPulse.com staff writers
The company expects full-year 2023 revenues to be in the range of $240 million to $260 million.
August 9, 2023
Graph Financial Results Tablet Social
Viome launches at-home oral disease test
By LabPulse.com staff writers
Viome uses the test results to provide consumers with customized food and supplement recommendations that support an individual’s oral and overall health, according to the company.
August 7, 2023
Oral Care Products Resized
Quest Diagnostics launches consumer-initiated genetic test kit
By LabPulse.com staff writers
The test uses next-generation sequencing (NGS) technology to analyze thousands of DNA variants in the genes associated with the conditions within the test’s scope, searching more regions in the individual’s genome than microarray testing.
July 12, 2023
Dna Genome Gene Targeted Social
Page 1 of 3
Next Page